GlassScriptPhysician profile
David Blaine Joyce
NPI 1114907243
$3,589.34
in general payments reported to CMS, 2019-2025
24 companies · $497 in 2025
The $497 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $925 · 2020: $195 · 2021: $641 · 2022: $80.88 · 2023: $913 · 2024: $338 · 2025: $497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,272 · Travel and Lodging: $476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,272.04 |
| Travel and Lodging | $475.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $749.75 | 2021-2024 | Simulus, Corevalve Evolut R |
| Abbott Laboratories | $582.67 | 2019-2025 | Amplatzer Amulet, Mitraclip, Thoratec Heartmate 3 Lvas Implant Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $222.30 | 2019-2024 | Jardiance |
| Amarin Pharma, INC. | $219.20 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $211.68 | 2019-2024 | Uptravi, Opsumit |
| Janssen Pharmaceuticals, INC | $203.95 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $165.71 | 2019-2025 | Camzyos |
| Boston Scientific Corporation | $160.83 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $150.47 | 2019-2024 | |
| Heartflow, INC. | $139.77 | 2023 | Ffrct |
| Abiomed | $129.37 | 2025 | |
| Pfizer INC. | $100.58 | 2019-2021 | |
| United Therapeutics Corporation | $97.96 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $92.34 | 2019-2021 | |
| Amgen INC. | $79.40 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $62.62 | 2019 | |
| Philips North America LLC | $41.84 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $39.47 | 2019-2021 | |
| Novo Nordisk INC | $32.94 | 2023-2024 | Rybelsus, Ozempic |
| Lundbeck LLC | $32.47 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $26.23 | 2019-2021 | |
| Esperion Therapeutics, INC. | $21.12 | 2021 | |
| Astellas Pharma US INC | $13.67 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $13.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Joyce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.